
Myriad Genetics, Inc.
NASDAQ•MYGN
CEO: Mr. Paul J. Diaz J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1995-10-06
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Contact Information
Market Cap
$547.16M
P/E (TTM)
-1.4
25.7
Dividend Yield
--
52W High
$15.47
52W Low
$3.76
52W Range
Rank52Top 73.5%
2.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$205.70M-3.56%
4-Quarter Trend
EPS
-$0.29+20.83%
4-Quarter Trend
FCF
$18.30M-426.79%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Major Impairment Charges Recorded Recognized $316.7M goodwill and asset impairment in nine months, driven by sustained market capitalization decline.
Financing Strengthens Cash Position Cash balance grew $45.0M to $154.8M, primarily due to proceeds from the new $125.0M term loan secured in July.
Revenue Declines Noted Total nine-month revenue fell $12.3M to $614.7M, heavily impacted by $22.1M drop in Pharmacogenomics sales.
Net Loss Significantly Widens Nine-month net loss reached $(358.0M), a substantial increase compared to the prior period's $(84.8M) loss.
Risk Factors
Coverage Changes Hurt Revenue UnitedHealthcare coverage changes negatively impact GeneSight test revenue; expect continued negative effects on Pharmacogenomics.
Profitability Not Yet Achieved Risk remains that growth targets will not materialize, preventing the company from achieving or maintaining future profitability.
Regulatory Oversight Uncertainty Future FDA legislative changes regarding LDTs could impose new compliance costs and cause delays in test development.
Key Personnel Transition Risks Recent senior leadership changes may create uncertainty, divert management attention, and hinder effective strategy execution.
Outlook
Focus on CCC Market Growth Strategy centers on driving accelerated growth in the Cancer Care Continuum market via R&D investment and commercial enhancement.
Leveraging Prenatal & GeneSight Aim to grow Prenatal Health and high-value GeneSight revenues above market growth rates using expanded offerings.
New Credit Facility Covenants New credit facility requires compliance with a minimum trailing twelve-month revenue test starting December 31, 2025.
Maintaining R&D Investment Committed to disciplined cost management while maintaining necessary investments in key strategic areas like research and development.
Peer Comparison
Revenue (TTM)
AMN$2.72B
MYGN$825.30M
CDNA$358.00M
Gross Margin (Latest Quarter)
IOVA97.9%
CSTL77.5%
MYGN69.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| OLMA | $1.98B | -14.4 | -41.5% | 1.3% |
| NRIX | $1.43B | -6.4 | -53.6% | 10.8% |
| CSTL | $1.23B | -86.5 | -2.7% | 6.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.8%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 23, 2026
EPS:-$0.02
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $205.70M-3.6%|EPS: $-0.29+20.8%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $213.10M+0.8%|EPS: $-3.57+770.7%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $195.90M-3.1%|EPS: $-0.00-99.6%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Revenue: $837.60M+11.2%|EPS: $-1.41+55.7%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 8, 2024|Revenue: $213.30M+11.2%|EPS: $-0.24-68.0%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 7, 2024|Revenue: $211.50M+15.3%|EPS: $-0.41-71.1%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $202.20M+11.6%|EPS: $-0.29-56.7%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 28, 2024|Revenue: $753.20M+11.0%|EPS: $-3.18-128.8%Miss